Effect of aerobic exercise and low carbohydrate diet on pre-diabetic non-alcoholic fatty liver disease in postmenopausal women and middle aged men - The role of gut microbiota composition: Study protocol for the AELC randomized controlled trial

BMC Public Health

Volumn 14, Issue 1, 2014, Pages

  Liu, Wu Yi ^a   Lu, Da Jiang ^a   Du, Xia Ming ^b   Sun, Jian Qin ^c   Ge, Jun ^b   Wang, Ren Wei ^a   Wang, Ru ^a   Zou, Jun ^a   Xu, Chang ^a   Ren, Jie ^a   Wen, Xin Fei ^a   Liu, Yang ^a,d   Cheng, Shu Mei ^d   Tan, Xiao ^d   Pekkala, Satu ^d   Munukka, Eveliina ^d   Wiklund, Petri ^d   Chen, Yan Qiu ^c   Gu, Qing ^b   Xia, Zheng Chang ^e   Liu, Jun Jun ^e   Liu, Wen Bin ^f   Chen, Xue Bo ^f   Zhang, Yi Min ^g   Li, Rui ^h   Borra, Ronald J H ^i,j   Yao, Jia Xin ^k   Chen, Pei Jie ^a   Cheng, Sulin ^a,d   more..

^a SHANGHAI UNIVERSITY OF SPORT   (China)

^b Shanghai Shidong Hospital   (China)

^c HUADONG HOSPITAL AFFILIATED TO FUDAN UNIVERSITY   (China)

^d UNIVERSITY OF JYVÄSKYLÄ   (Finland)

^e Dept of Internal Medicine Yanji Community Health Service Centre of Yangpu District   (China)

^f Wujiaochang Health Care Service Centre   (China)

^g BEIJING SPORT UNIVERSITY   (China)

^h SHANGHAI MUNICIPAL CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

ⁱ MASSACHUSETTS GENERAL HOSPITAL   (United States)

^j TURKU UNIVERSITY HOSPITAL   (Finland)

^k TIANJIN UNIVERSITY OF SPORT   (China)

more..

Author keywords

Clinical setting; Glucose metabolism; Gut microbiota; Human; Lipid metabolism; Liver fat content; Metabonomics

Indexed keywords

EID: 84892458342     PISSN: None     EISSN: 14712458     Source Type: Journal    
DOI: 10.1186/1471-2458-14-48     Document Type: Article

References (37)

1. GI epidemiology: nonalcoholic fatty liver disease. Angulo P, Aliment Pharmacol & Ther 2007 25 8 883 889 10.1111/j.1365-2036.2007.03246.x 17402991
2. Epidemiology of non-alcoholic fatty liver disease in China. Fan JG, Farrell GC, J of Hepatol 2009 50 1 204 210 10.1016/j.jhep.2008.10.010
3. Increasing trend in the prevalence of Type 2 diabetes and pre-diabetes in the Chinese rural and urban population in Qingdao, China. Gao WG, Dong YH, Pang ZC, Nan HR, Zhang L, Wang SJ, Ren J, Ning F, Qiao Q, Diabet Med: a J of the British Diabet Assoc 2009 26 12 1220 1227 10.1111/j.1464-5491.2009.02832.x
4. Diabetes and pre-diabetes as determined by glycated haemoglobin A1c and glucose levels in a developing southern Chinese population. Zhang YH, Ma WJ, Thomas GN, Xu YJ, Lao XQ, Xu XJ, Song XL, Xu HF, Cai QM, Xia L, et al. PloS one 2012 7 5 37260 10.1371/journal.pone.0037260 22615957
5. Gut microbiota: changes throughout the lifespan from infancy to elderly. O'Toole PW, Claesson MJ, Int Dairy J 2010 20 4 281 291 10.1016/j.idairyj.2009. 11.010
6. Human nutrition, the gut microbiome and the immune system. Kau AL, Ahern PP, Griffin NW, Goodman AL, Gordon JI, Nature 2011 474 7351 327 336 10.1038/nature10213 21677749
7. Gut microbiota in health and disease. Sekirov I, Russell SL, Antunes LC, Finlay BB, Physiol Rev 2010 90 3 859 904 10.1152/physrev.00045.2009 20664075
8. Women with and without metabolic disorder differ in their gut microbiota composition. Munukka E, Wiklund P, Pekkala S, Volgyi E, Xu L, Cheng S, Lyytikainen A, Marjomaki V, Alen M, Vaahtovuo J, et al. Obesity (Silver Spring, Md) 2012 20 5 1082 1087 10.1038/oby.2012.8
9. Gut microbiota in human adults with type 2 diabetes differs from non-diabetic adults. Larsen N, Vogensen FK, van den Berg FW, Nielsen DS, Andreasen AS, Pedersen BK, Al-Soud WA, Sorensen SJ, Hansen LH, Jakobsen M, PloS one 2010 5 2 9085 10.1371/journal.pone.0009085 20140211
10. A complex microworld in the gut: gut microbiota and cardiovascular disease connectivity. Howitt MR, Garrett WS, Nat Med 2012 18 8 1188 1189 10.1038/nm.2895 22869188
11. Structural modulation of gut microbiota in life-long calorie-restricted mice. Zhang C, Li S, Yang L, Huang P, Li W, Wang S, Zhao G, Zhang M, Pang X, Yan Z, et al. Nat Commun 2013 4 2163 23860099
12. Obesity, diabetes, and gut microbiota: the hygiene hypothesis expanded? Musso G, Gambino R, Cassader M, Diabet care 2010 33 10 2277 2284 10.2337/dc10-0556
13. The role of the gut microbiota in nonalcoholic fatty liver disease. Abu-Shanab A, Quigley EM, Nat Rev Gastroenterol & Hepatol 2010 7 12 691 701 10.1038/nrgastro.2010.172 21045794
14. Gut microbiota in obesity and metabolic disorders. Sanz Y, Santacruz A, Gauffin P, Proc Nutr Soc 2010 69 3 434 441 10.1017/S0029665110001813 20540826
15. Gut microbiota, lipopolysaccharides, and innate immunity in the pathogenesis of obesity and cardiovascular risk. Manco M, Putignani L, Bottazzo GF, Endocr Rev 2010 31 6 817 844 10.1210/er.2009-0030 20592272
16. Pathogenesis of type 1 diabetes mellitus: interplay between enterovirus and host. Hober D, Sauter P, Nat Rev Endocrinol 2010 6 5 279 289 10.1038/nrendo.2010.27 20351698
17. Enteroviruses and type 1 diabetes: towards a better understanding of the relationship. Jaidane H, Sauter P, Sane F, Goffard A, Gharbi J, Hober D, Rev in Med Virol 2010 20 5 265 280 10.1002/rmv.647
18. Viral obesity: fact or fiction? Mitra AK, Clarke K, Obes Rev 2009 11 4 289 296 19874530
19. Voluntary running exercise alters microbiota composition and increases n-butyrate concentration in the rat cecum. Matsumoto M, Inoue R, Tsukahara T, Ushida K, Chiji H, Matsubara N, Hara H, Biosci, Biotechnol, and Biochem 2008 72 2 572 576 10.1271/bbb.70474 (Pubitemid 351353675)
20. Microbial ecology: human gut microbes associated with obesity. Ley RE, Turnbaugh PJ, Klein S, Gordon JI, Nature 2006 444 7122 1022 1023 10.1038/4441022a 17183309 (Pubitemid 46018512)
21. Randomized trial of exercise effect on intrahepatic triglyceride content and lipid kinetics in nonalcoholic fatty liver disease. Sullivan S, Kirk EP, Mittendorfer B, Patterson BW, Klein S, Hepatol (Baltimore, Md) 2012 55 6 1738 1745 10.1002/hep.25548
22. A meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease. Musso G, Gambino R, Cassader M, Pagano G, Hepatol (Baltimore, Md) 2010 52 1 79 104 10.1002/hep.23623
23. Nonalcoholic fatty liver disease: rapid evaluation of liver fat content with in-phase and out-of-phase MR imaging. Borra RJ, Salo S, Dean K, Lautamaki R, Nuutila P, Komu M, Parkkola R, Radiology 2009 250 1 130 136 10.1148/radiol.2501071934 19017926
24. Endpoints and clinical trial design for nonalcoholic steatohepatitis. Sanyal AJ, Brunt EM, Kleiner DE, Kowdley KV, Chalasani N, Lavine JE, Ratziu V, McCullough A, Hepatol (Baltimore, Md) 2011 54 1 344 353 10.1002/hep.24376
25. Comparison of vertebral bone marrow fat assessed by H MRS and inphase and out-of-phase MRI among family members. Ojanen X, Borra RJ, Havu M, Cheng SM, Parkkola R, Nuutila P, Alen M, Cheng S, Osteoporos Int 2013 DOI 10.1007/S00198-013-2472-9
26. Automatic quantitation of localized in vivo 1H spectra with LCModel. Provencher SW, NMR in Biomed 2001 14 4 260 264 10.1002/nbm.698 (Pubitemid 32611437)
27. Validity of a two kilometre walking test for estimating maximal aerobic power in overweight adults. Laukkanen R, Oja P, Pasanen M, Vuori I, Int J of Obe and Relat Metab Dis: J of the Int Assoc for the Study of Obes 1992 16 4 263 268
28. Predicting maximum oxygen uptake from a modified 3-minute step test. Santo AS, Golding LA, Res Q for Exerc and Sport 2003 74 1 110 115 10.1080/02701367.2003.10609070 (Pubitemid 44524942)
29. Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. Neuschwander-Tetri BA, Caldwell SH, Hepatol (Baltimore, Md) 2003 37 5 1202 1219 10.1053/jhep.2003.50193 (Pubitemid 36538699)
30. Prediction of diabetes using ADA or WHO criteria in post-menopausal women: a 10-year follow-up study. Larsson H, Lindgarde F, Berglund G, Ahren B, Diabetologia 2000 43 10 1224 1228 10.1007/s001250051516 11079739
31. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Pan XR, Li GW, Hu YH, Wang JX, Yang WY, An ZX, Hu ZX, Lin J, Xiao JZ, Cao HB, et al. Diabet care 1997 20 4 537 544 10.2337/diacare.20.4.537 (Pubitemid 27143412)
32. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. Tuomilehto J, Lindstrom J, Eriksson JG, Valle TT, Hamalainen H, Ilanne-Parikka P, Keinanen-Kiukaanniemi S, Laakso M, Louheranta A, Rastas M, et al. The New England J of Med 2001 344 18 1343 1350 10.1056/NEJM200105033441801 (Pubitemid 32378388)
33. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM, The New England J of Med 2002 346 6 393 403 (Pubitemid 34437694)
34. Gut microbiota and non-alcoholic fatty liver disease: new insights. Aron-Wisnewsky J, Gaborit B, Dutour A, Clement K, Clin Microbiol and Infect: the official publication of the European Soc of Clin Microbiol and Infect Dis 2013 19 4 338 348 10.1111/1469-0691.12140
35. Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet-induced obesity and diabetes in mice. Cani PD, Bibiloni R, Knauf C, Waget A, Neyrinck AM, Delzenne NM, Burcelin R, Diabetes 2008 57 6 1470 1481 10.2337/db07-1403 18305141
36. Gut microbiota composition in male Rat models under different nutritional status and physical activity and its association with serum leptin and ghrelin levels. Queipo-Ortuno MI, Seoane LM, Murri M, Pardo M, Gomez-Zumaquero JM, Cardona F, Casanueva F, Tinahones FJ, PloS one 2013 8 5 65465 10.1371/journal.pone.0065465 23724144
37. Gut microbiota and nonalcoholic fatty liver disease. Machado MV, Cortez-Pinto H, Ann of Hepatol 2012 11 4 440 449